Buprenorphine HCl and Naloxone HCl
- Product NDC
- 50268-145
- Requested package NDC
- 50268-145-15
- 11-digit product format
- 502680145
- Labeler code
- 50268
- Product ID
- 50268-145_47e23f4e-d4aa-7af1-e063-6394a90a2f05
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Buprenorphine and Naloxone
- Dosage form
- TABLET
- Route
- SUBLINGUAL
- Labeler
- AvPAK
- Application
- ANDA203136
- Marketing category
- ANDA
- Marketing start
- 2016-12-08
- Substance
- BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE DIHYDRATE
- Active strength
- 8; 2 mg/1; mg/1
- Pharmacologic classes
- Opioid Antagonist [EPC], Opioid Antagonists [MoA], Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]
- DEA schedule
- CIII
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | |
| A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203136-001 | AB |
| A203136-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203136-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203136-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2013-02-22 | 74a2ff9319b5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203136-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A203136-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203136-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203136-002 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A203136-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A203136-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203136-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203136-002 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203136-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A203136-002 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203136-001 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203136-002 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203136-001 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203136-002 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203136-001 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203136-002 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203136-001 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203136-002 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203136-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203136-002 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203136-001 | AB | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203136-002 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A203136-001 | AB | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A203136-002 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203136-001 | AB | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203136-002 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203136-001 | AB | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203136-002 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203136-001 | AB | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203136-002 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A203136-001 | AB | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A203136-002 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203136-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203136-002 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A203136-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A203136-002 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A203136-001 | AB | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A203136-002 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A203136-001 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A203136-002 | AB | 1 | 74a2ff9319b5… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Buprenorphine HCl and Naloxone HCl
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| BUPRENORPHINE HYDROCHLORIDE | 8 mg/1 |
| NALOXONE HYDROCHLORIDE DIHYDRATE | 2 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 56W8MW3EN1 | Internal UNII lookup |
| 5Q187997EE | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| b955054b-b37d-4079-4fed-5939b763ecb4 | Available on FDA.report |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50268-145-11 | Buprenorphine HCl and Naloxone HCl | 1 in 1 BLISTER PACK | TABLET | 1 | 11 | |
| 50268-145-15 | Buprenorphine HCl and Naloxone HCl | 50 in 1 BOX, UNIT-DOSE | TABLET | 50 | 11 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50268-145-11 | EA - Each | 50268-145 | d2f345ae-944d-462d-9cb0-e9bb27d235ab | 1 | 2017-03-06 |
| 50268-145-15 | EA - Each | 50268-145 | e7500757-bb95-42a9-9202-57ff0d557317 | 1 | 2017-03-06 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | e82e2d74-33a8-4894-82f6-788fc0f9feec | 2026-06-08 | Warnings, Adverse reactions | 203136 ANDA203136 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2aaad1a7-a0fd-4dd5-bb53-03afad8f10b9 | 2026-04-03 | Warnings, Adverse reactions | 203136 ANDA203136 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Amneal Pharmaceuticals LLC | 17b63f10-c9df-44be-80fa-6f1c305583b8 | 2026-02-02 | Warnings, Adverse reactions | 203136 ANDA203136 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | AvPAK | b955054b-b37d-4079-4fed-5939b763ecb4 | 2026-01-08 | Warnings, Adverse reactions | 203136 ANDA203136 50268-145-15 50268-145 50268014515 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 351266 | buprenorphine HCl 2 MG / naloxone HCl 0.5 MG Sublingual Tablet | PSN | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
| 351267 | buprenorphine HCl 8 MG / naloxone HCl 2 MG Sublingual Tablet | PSN | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
| 351266 | buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet | SCD | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
| 351267 | buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet | SCD | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
| 351266 | buprenorphine 2 MG (as buprenorphine HCl) / naloxone 0.5 MG (as naloxone HCl) Sublingual Tablet | SY | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
| 351267 | buprenorphine 8 MG (as buprenorphine HCl) / naloxone 2 MG (as naloxone HCl) Sublingual Tablet | SY | b955054b-b37d-4079-4fed-5939b763ecb4 | 11 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 50268-145-15 | 50268014515 | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-145-15) / 1 TABLET in 1 BLISTER PACK (50268-145-11) | 50 blister pack | 2016-12-08 | 0000-00-00 | No | No | Current |